CD4 and colorectal carcinoma: In addition, a programmed death-ligand 1 (PDL-1)-mediated inhibition of the antitumor activity of CD4+ and CD8+ T cells has been noted in breast cancers and CRC due to their metabolic activity modulation [5,28].